Castlefield Investment Partners LLP purchased a new stake in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, Holdings Channel reports. The firm purchased 41,797 shares of the company’s stock, valued at approximately $5,371,000. Merck KGaA makes up 3.6% of Castlefield Investment Partners LLP’s portfolio, making the stock its 11th largest position.
A number of other large investors have also made changes to their positions in MKGAF. Frazier Financial Advisors LLC acquired a new stake in Merck KGaA during the 2nd quarter worth $25,000. Rakuten Securities Inc. acquired a new position in Merck KGaA in the second quarter valued at about $27,000. Solstein Capital LLC acquired a new position in Merck KGaA in the second quarter valued at about $33,000. Burk Holdings LLC bought a new stake in shares of Merck KGaA in the second quarter worth about $39,000. Finally, Bard Associates Inc. bought a new stake in shares of Merck KGaA in the second quarter worth about $60,000. Institutional investors own 0.10% of the company’s stock.
Merck KGaA Stock Performance
OTCMKTS MKGAF opened at $163.21 on Monday. The firm has a market cap of $21.09 billion, a P/E ratio of 24.92 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The stock’s 50-day moving average is $162.62 and its 200-day moving average is $148.44. Merck KGaA has a one year low of $116.68 and a one year high of $175.56.
About Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Articles
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
